Cite
HARVARD Citation
O'Day, S. et al. (n.d.). 423 Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors. Journal for immunotherapy of cancer. pp. A257-A258. [Online].